AMGN vs TMO: Amgen Inc. vs Thermo Fisher Scientific Inc.
Side-by-side snapshot of two Healthcare companies — key metrics from our latest data. Reference only, not investment advice.
| Metric | AMGN | TMO |
|---|---|---|
| Company | Amgen Inc. | Thermo Fisher Scientific Inc. |
| Price | $437.23 | $613.78 |
| Market Cap | $236.38B | $226.94B |
| P/E Ratio | 27.17 | 33.00 |
| EPS | $16.09 | $18.60 |
| Dividend Yield | 2.31% | 0.31% |
| 52-Week High | $447.03 | $647.00 |
| 52-Week Low | $269.77 | $435.27 |
| Beta | 0.43 | 0.85 |
| Return on Equity (ROE) | 91.47% | 13.51% |
| Debt-to-Equity | 490.28% | 80.58% |
| Industry | Drug Manufacturers - General | Diagnostics & Research |
| Exchange | NMS | NYQ |
| Employees | 31,500 | 125,000 |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Jack Bogle's case for low-cost index funds, in under 300 pages.
Check Price →A desk whiteboard for tracking tickers, levels and ideas at a glance.
Check Price →JL Collins' plain-English guide to index investing and financial independence.
Check Price →Amgen Inc. and Thermo Fisher Scientific Inc. both operate in the Healthcare sector. AMGN has a market cap of $236.38B versus TMO's $226.94B. On valuation, AMGN carries a trailing P/E of 27.17 against 33.00 for TMO. In terms of earnings, AMGN posts EPS of $16.09 versus TMO's $18.60. For price range, AMGN has traded between $269.77 and $447.03 over the past 52 weeks, and TMO between $435.27 and $647.00. On income, AMGN yields 2.31% versus TMO's 0.31%. On volatility, TMO carries the higher beta (AMGN 0.43 vs TMO 0.85), meaning it has historically moved more sharply than the market. How these figures compare depends on each company's growth profile, margins and competitive position — this snapshot is a starting point for research, not a recommendation.
Comparing two companies becomes much more powerful once you can read their financials directly — financial statement analysis guides are a practical next step. Many investors track comparisons like this in a dedicated stock research journal.
Figures are from our latest data snapshot and may not reflect current market prices. See the full profiles: Amgen Inc. and Thermo Fisher Scientific Inc.. This is not financial advice.
Recommended Reading
Philip Fisher's growth-investing classic on evaluating management and moats.
Check Price →Tidy statements, reports and research with a simple desk filing organizer.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →